Protein blood test aims to personalize heart care, but study stalls

NCT ID NCT04836117

Terminated Knowledge-focused Sponsor: Intermountain Health Care, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a new blood test called SomaSignal could help doctors make better treatment decisions for people at higher risk of heart disease. The test measures proteins in the blood to predict heart risks. Only 12 people took part before the study was stopped early, so we have very little information on whether it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SomaSignal Test (protein-based blood test)
What this could lead to: If successful, this test could help doctors personalize heart disease prevention by identifying who needs more aggressive treatment.
What could go wrong: The study was terminated early with only 12 participants, so results are very limited. It is not clear if the test actually improves health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Health Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTH BEHAVIOR

Contacts and locations

Locations

Intermountain Medical Center

Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.